

Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience

Giada Del Baldo, Andrea Carai, Rachid Abbas, Antonella Cacchione, Mara Vinci, Valentina Di Ruscio, Giovanna Stefania Colafati, Sabrina Rossi, Francesca Diomed Camassei, Nicola Maestro, Sara Temelso, Giulia Pericoli, Emmanuel De Billy, Isabella Giovannoni, Alessia Carboni, Martina Rinelli, Emanuele Agolini, Alan Mackay, Chris Jones, Silvia Chiesa, Mario Balducci, Franco Locatelli* and Angela Mastronuzzi*

Abstract

Background: Diffuse intrinsic pontine glioma (DIPG) is a fatal disease with a median overall survival (OS) of less than 12 months after diagnosis. Radiotherapy (RT) still remains the mainstay treatment. Several other therapeutic strategies have been attempted in the last years without a significant effect on OS. Although radiological imaging is the gold standard for DIPG diagnosis, the urgent need to improve the survival has led to the reconsideration of biopsy with the aim to better understand the molecular profile of DIPG and support personalized treatment.

Methods: In this study, we present a single-center experience in treating DIPG patients at disease progression combining targeted therapies with standard of care. Biopsy was proposed to all patients at diagnosis or disease progression. First-line treatment included RT and nimotuzumab/vinorelbine or temozolomide. Immunohistochemistry-targeted research included study of mTOR/p-mTOR pathway and *BRAFv600E*. Molecular analyses included polymerase chain reaction, followed by Sanger sequences and/or next-generation sequencing.

Results: Based on the molecular profile, targeted therapy was administered in 9 out of 25 patients, while the remaining 16 patients were treated with standard of care. Personalized treatment included inhibition of the PI3K/AKT/mTOR pathway (5/9), PI3K/AKT/mTOR pathway and *BRAFv600E* (1/9), *ACVR1* (2/9) and *PDGFRA* (1/9); no severe side effects were reported during treatment. Response to treatment was evaluated according to Response Assessment in Pediatric Neuro-Oncology criteria, and the overall response rate within the cohort was 66%. Patients treated with targeted therapies were compared with the control cohort of 16 patients. Clinical and pathological characteristics of the two cohorts were homogeneous. Median OS in the personalized treatment and control cohort was 20.26 and 14.18 months, respectively ($p=0.032$). In our experience, the treatment associated with the best OS was everolimus.

Conclusion: Despite the small simple size of our study, our data suggest a prognostic advantage and a safe profile of targeted therapies in DIPG patients, and we strongly advocate to reconsider the role of biopsy for these patients.

Keywords: biopsy, DIPG, molecular profile, pediatric brain tumors, targeted therapy

Received: 9 December 2021; revised manuscript accepted: 28 June 2022.

Introduction

Diffuse intrinsic pontine glioma (DIPG), accounting for about 10% of all brain malignancies, is the deadliest pediatric central nervous system tumor.^{1,2} The median progression-free survival

(PFS) is 7 months and less than 10% of the patients survive 2 years after diagnosis.^{3,4}

Magnetic resonance imaging (MRI) is the gold standard for DIPG diagnosis.⁵ Typical MRI

Ther Adv Med Oncol

2022, Vol. 14: 1–19

DOI: 10.1177/
17588359221113693

© The Author(s), 2022.
Article reuse guidelines:
sagepub.com/journals-
permissions

Correspondence to:
Andrea Carai
Neurosurgery Unit,
Department of
Neurosciences, Bambino
Gesù Children's Hospital,
IRCCS, Piazza Sant'Onofrio
4, 00165 Rome, Italy
andrea.carai@opbg.net

Giada Del Baldo
Antonella Cacchione
Mara Vinci
Valentina Di Ruscio
Nicola Maestro
Giulia Pericoli
Emmanuel De Billy
Angela Mastronuzzi
Department of Pediatric
Haematology and
Oncology, and Cell and
Gene Therapy, Bambino
Gesù Children's Hospital,
IRCCS, Rome, Italy

Rachid Abbas
CESP, INSERM, Université
Paris Sud, Villejuif, France

Giovanna Stefania Colafati
Alessia Carboni
Oncological
Neuroradiology Unit,
Imaging Department,
Bambino Gesù Children's
Hospital, IRCCS, Rome,
Italy

Sabrina Rossi
Francesca
Diomed Camassei
Isabella Giovannoni
Pathology Unit,
Department of
Laboratories, Bambino
Gesù Children's Hospital,
IRCCS, Rome, Italy

Sara Temelso
Alan Mackay
Chris Jones
Division of Molecular
Pathology, The Institute of
Cancer Research, London,
UK

Division of Cancer
Therapeutics, The Institute
of Cancer Research,
London, UK

Martina Rinelli
Emanuele Agolini
Laboratory of Medical
Genetics, Bambino Gesù
Children's Hospital, IRCCS,
Rome, Italy

Silvia Chiesa
Mario Balducci
Department of
Radiotherapy, Fondazione
Policlinico Universitario
"A. Gemelli," Catholic
University of Sacred Heart,
Rome, Italy

Franco Locatelli
Department of Pediatric
Haematology and Oncology,
and Cell and Gene Therapy,
Bambino Gesù Children's
Hospital, IRCCS, Rome, Italy
Department of Life
Sciences and Public Health,
Fondazione Policlinico
Universitario "A. Gemelli,"
Catholic University of
Sacred Heart, Rome, Italy
*Co-last authorship

findings reveal a large expansive pontine lesion, occupying more than 50% of its ventral portion that appears hypointense or isointense on T1-weighted (T1w) imaging, and hyperintense on T2-weighted (T2w) imaging and on fluid-attenuated inversion recovery (FLAIR) imaging.⁵

Radiotherapy (RT) remains the mainstay treatment for DIPG, a clinical and radiological response being observed in about 70% of patients⁶; meanwhile, several chemotherapeutic strategies have been explored in different clinical trials during the last 30 years, but, unfortunately, none of them were shown to induce complete remission of the disease.^{3,7–12}

To date, standardized therapy has improved PFS and time to progression (TTP) with no impact on overall survival (OS) in these patients.^{6,13} Recent study confirms a median OS of 11 months (interquartile range: 7.5–16).¹⁴

Analysis on autaptic samples demonstrated that DIPGs present an overexpression/activation of epidermal growth factor receptor (EGFR) protein. Investigating EGFR protein role, Massimino *et al.*¹⁵ proposed the clinical use of anti-EGFR monoclonal antibody, nimotuzumab, in combination with RT and vinorelbine as a potential synergic treatment strategy, reporting the best OS with a median time of 15 months in patients treated with this approach.

Tumor biopsy is not mandatory for DIPG diagnosis and is currently indicated in the presence of atypical radiological features or in the setting of a clinical trial.¹⁶ The role of biopsy is increasingly being redefined over time, enabling to conduct biology-driven translational research, supporting target therapy, and allowing advanced clinical trial studies, as well as contributing to better detail the disease diagnosis.¹⁷

More than 80% of DIPGs harbor a mutation in the H3 genes, especially in the N-terminal tail of histone H3, with a substitution of lysine at position 27.¹⁸ The H3K27M mutation and the loss of H3K27me3 are the paramount features of DIPG. Molecular studies have unveiled numerous shared genetic alterations, with a striking prevalence of the K27M mutation in genes encoding the histones H3.3 and H3.1, mutually exclusive in DIPG.¹⁸

Additional recurrent mutations have also been identified. Mutations in *ACVR1* co-occur in

20–30% of H3-mutated DIPG, and mutations in TP53 are found in up to 77% of these tumors.¹⁹

Since the discovery of the K27M mutation in the H3 histone genes,^{20,21} many co-segregating mutations have been unveiled,²² on which much effort has been made in exploring the possibility of targeted therapeutic approaches.²³

Here, we present our experience in treating DIPG patients at the time of disease progression, combining targeted therapy to our institutional second-line treatment and discuss the benefit of such approach.

Materials and methods

This study includes children with a diagnosis of DIPG who were admitted to Bambino Gesù Children's Hospital in Rome from 2014 to 2019.

Radiology

MRI examinations were performed on a 3 Tesla (3 T) magnet (Siemens Magnetom Vision Plus, c Erlangen, Germany), and general anesthesia was utilized for non-cooperating children. The MRI was extended to whole brain and spinal cord, with at least T1w sagittal, T1w and T2w axial sequences, FLAIR, T2w coronal and diffusion-weighted imaging (DWI) sequences. Acquisition protocols employed 3 mm of slice thickness.⁵ Radiological response during treatment was evaluated by an experienced neuroradiologist (GSC) in accordance with the response assessment in neuro-oncology (RANO) criteria.²⁴ To confirm treatment response according to the most recent Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria²⁵ specific for DIPG, all cases were retrospectively reviewed by a blinded experienced neuroradiologist (GSC).

Frameless stereotactic biopsy

Biopsy was proposed to all patients at the time of diagnosis or at first progression. Robot-assisted stereotactic needle biopsy was performed using a trans-frontal approach as previously described by our group.²⁶ Biopsy samples were used for diagnostic and translational research purposes, according to the following prioritization: (a) histology and immunostaining for H3K27M; (b) molecular analysis:

Sanger sequencing or next-generation sequencing (NGS); (c) immunohistochemistry (IHC) target detection; and (d) establishment of cell cultures.

Pathology and IHC

IHC was carried out on formalin-fixed paraffin-embedded sections using an automated immunostainer (Dako Omnis, Agilent, Santa Clara, CA USA). Primary antibodies directed against the following antigens were applied: ATRX (clone AX1, 1/100, high pH, Dianova, Hamburg, Germany), GFAP (polyclonal, prediluted, high pH, Dako, Santa Clara, USA), H3K27M (polyclonal, 1/1500, high pH, Millipore, Danvers, Massachusetts, USA), H3.3K27me3 (clone C36B11, 1/200, low pH, Cell Signaling technology), Ki67 (clone MIB-1, prediluted, low pH, Dako, Santa Clara, USA), OLIG2 (1/20, high pH, Quartett, Schichauweg, Berlin, Germany), p53 (clone DO-7, prediluted, high pH, Dako, Santa Clara, USA), *BRAF*^{v600E} (clone VE1, 1/50, high pH, Spring Bioscience Corp., 4300 Hacienda Dr, Pleasanton, CA 94588, USA), mTOR (clone 7C10 1:50, high pH, Cell Signaling Technology, Danvers, Massachusetts, USA) and p-mTORSer2448 (D9C2, 1:100, high pH, Cell Signaling Technology, Danvers, Massachusetts, USA). P53 was interpreted as overexpressed when nuclear staining was seen in 50% of the neoplastic cells or more. Ki67 was expressed as percentage of positive neoplastic cells.

DNA extraction from snap frozen tissue and Sanger sequencing

DNA was extracted from snap frozen tissue following the DNeasy Blood & Tissue kit protocol (Qiagen, Germany), while for FFPE tumor tissue, cores were taken from tumor area and used for genomic DNA isolation, following NucleoSpin tissue kit protocol (Macherey-Nagel). DNA concentration was determined on a Nanodrop 2000 (Thermo Fisher, Waltham, Massachusetts, USA). Polymerase chain reaction (PCR) was carried out as previously described²⁷ to analyze hotspot mutations for the following genes: H3F3A (NM_002107), HIST1H3B (NM_003537), HIST1H3C (NM_003531), and HIST2H3C (NM_003531), along with exons 4–7 of ACVR1 (NM_001105), using primers obtained from Sigma Aldrich (St. Louis, Missouri, USA).²⁷

Products were purified using NucleoSpin Gel and PCR Clean-up (Macherey-Nagel, Germany), quantified on a Nanodrop 2000 (Thermo

Scientific, Waltham, Massachusetts, USA) and subjected to bidirectional sequencing using BigDye Terminator v3.1 (Applied Biosystem™, Waltham, Massachusetts, USA). After purification with Nucleoseq (Macherey Nagel, Germany), capillary sequencing was performed on a 3500 Genetic analyser (Applied Biosystem™, Waltham, Massachusetts, USA). Sequences were analyzed using the Mutation Surveyor (SoftGenetics, Pennsylvania, USA) and manually with FinchTV (Geospiza, Seattle, USA). Mutations were called when an aberrant peak was clearly distinguishable from background noise in both the forward and reverse sequence, or if an aberrant peak was identified by the software in at least one of the sequences and confirmed by visual inspection. The new putative variants identified were compared with the somatic mutations listed in the COSMIC (<https://cancer.sanger.ac.uk/cosmic>), VarSome (<https://varsome.com/>) and dbSNP (<https://www.ncbi.nlm.nih.gov/snp/>) databases. Silico tools such as PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) and Provean (<http://provean.jcvi.org/index.php>) were used to predict whether an amino acid substitution had an impact on the biological function of the protein ACVR1.

Next-generation sequencing

DNA sequencing was performed by means of an IDT-xGen Predesigned Gene Capture Panel (Integrated DNA Technologies, Leuven, Belgium) for a total of 336 genes, of which 99 genes reportedly mutated in pediatric high-grade gliomas and other pediatric brain tumors;^{28–30} and the others were used to investigate cancer predisposition syndromes. DNA libraries were prepared using the Nextera™ DNA Flex Library Prep (Illumina, San Diego, CA, USA) according to the manufacturer's protocols, and sequencing was done on a NextSeq 550 (Illumina). The fastq files were aligned to the human reference GRCh37/hg19. The BWA Enrichment application of BaseSpace (Illumina) and the TGex software (LifeMap Sciences) were used for the calling and annotating variants, respectively. Sequence data were carefully analyzed, and the presence of all suspected variants was checked in the public databases [dbSNP; <http://www.ncbi.nlm.nih.gov/projects/SNP>], 1000 Genomes Project (<http://www.internationalgenome.org/>), EVS (<http://evs.gs.washington.edu/EVS/>), ExAC (<http://exac.broadinstitute.org/>), gnomAD (<http://gnomad.broadinstitute.org/>), and Cosmic (<https://cancer.sanger.ac.uk/cosmic>). Sequencing

data filtering was performed to identify germline and somatic pathogenic or likely pathogenic variants with an allele frequency <1%, according to dbSNP's overall frequency that results in a change in the amino acid sequence (i.e. missense/nonsense) or that reside within a putative splice site junction (with a window size of 7 bases). Functional impact of variants was analyzed by Combined Annotation Dependent Depletion V.1.3, Sorting Intolerant from Tolerant, and Polymorphism Phenotyping v2 (PolyPhen-2). Selected variants were interpreted in accordance with the American College of Medical Genetics and Genomics/Association for Molecular Pathology. Variants were examined for coverage and Q-score (minimum threshold of 30) and were visualized by the Integrative Genome Viewer.

Patient's treatment

First-line treatment consisted of focal RT associated with nimotuzumab and vinorelbine.¹⁵ Two patients had received temozolomide associated with RT at other institutions, prior to admission to our hospital. Patient-adapted treatment regimens were used at the time of progression. Re-irradiation was performed when progression occurred at least 6 months after previous RT.³¹ Second-line chemotherapy included bevacizumab and temozolomide, or nimotuzumab/vinorelbine, when not performed as first-line treatment.

At progression, based on their tumor molecular makeup, patients were assigned to a targeted treatment plan, in accordance with the multidisciplinary molecular tumor board's consensus report. Targeted treatments included everolimus, vemurafenib, pazopanib, and palovarotene, which when appropriate were used individually or in combination. Posology was chosen according to the literature data and previously reported experience in the pediatric population.^{32–34} Drugs against selected targets were associated with concomitant chemotherapy in all cases. Treatment side effects were reported according to Common Terminology Criteria for Adverse Effects (AE) 5.0 version.

Statistical analysis

Patients were stratified in two groups according to treatment received: targeted *versus* non-targeted treatment. Comparison tests included

Fisher's exact test and Student's *t* test distribution. OS was defined as the time from diagnosis to death, and survival after the first progression (SFP) was defined as the time from first progression of the disease to death. TTP was described in the target population as the time from start of targeted therapy to progression.

OS and SFP were calculated using the Kaplan–Meier method. Survival curves were compared with log-rank tests; multivariate analyses were not performed due to the limited sample sizes. All comparison tests were two-sided and considered significant at the 5% level. SAS 9.4 version software was used for statistical analysis.

Results

Between 2015 and 2019, we enrolled 25 DIPG patients at diagnosis or progression who were being treated at the Bambino Gesù Children's Hospital. All patients fulfilled radiologic criteria for DIPG diagnosis.

Median age at diagnosis was 6.1 years (range: 3.6–14.7), and 16/25 (64%) patients were female. Main clinical and radiological characteristics according to the treatment stratification (targeted *versus* other treatments) are detailed in Table 1.

Metastatic disease at diagnosis was excluded on the basis of cerebrospinal fluid cytology and MRI in all cases.

Biopsy

Biopsy was performed in all cases. None of the patients showed hemorrhage at the postoperative imaging and no irreversible neurological deficit was observed; confirming biopsy safety. Only three patients presented transient neurologic impairment after biopsy, completely resolved after maximum 2 months. A flow chart showing the investigation carried out on tumor samples is described in Figure 1.

Collected samples allowed pathological diagnosis of DIPG in all cases:

- (a) Expression of glial markers, that is, GFAP and/or OLIG2, and the presence of the H3K27M mutation by the mutation-specific antibody was explored in all cases. IHC showed H3K27M mutation in 24/25 cases. H3.3K27me3 loss of expression was

Table 1. Patient, tumor, and first-line treatment characteristics.

Characteristics	Target therapy (n = 9)	No-target therapy (n = 16)
Gender		
Male:Female	3:6	6:10
Age (years)		
Median (range)	6.01 years (5.04–11.93)	6.07 years (3.6–14.71)
Duration of symptoms		
<1 month	3 (33%)	5 (31%)
1–2 months	5 (56%)	8 (50%)
>3 months	1 (11%)	3 (19%)
Neurological signs		
Cranial nerve deficit	5 (56%)	12 (75%)
Cerebellar signs	3 (33%)	3 (19%)
Long tract signs	1 (11%)	1 (6%)
Radiological features		
Pons involvement > 50%	9 (100%)	16 (100%)
Tumor extension beyond the pons		
No	1 (11%)	0
Yes	8 (89%)	16 (100%)
Cerebellum	5 (62.5%)	6 (37.5%)
Midbrain	8 (100%)	15 (94%)
Thalami	0	4 (25%)
Medulla	0	2 (12.5%)
Internal capsule	0	4 (25%)
Tumor morphology		
Margins	6 (67%)	14 (87.5%)
Eccentric	6 (67%)	7 (44%)
Exophytic	9 (100%)	15 (94%)
Tumor signal		
T1 hypointensity, T2 hyperintensity	9 (100%)	16 (100%)

(Continued)

Table 1. (Continued)

Characteristics	Target therapy (n = 9)	No-target therapy (n = 16)
Enhancement		
Homogeneous	0	0
Heterogeneous	1 (11%)	3 (19%)
Ring enhancement	4 (45%)	6 (37.5%)
Patchy enhancement	2 (22%)	3 (19%)
Encasement of basilar artery	9 (100%)	16 (100%)
Diffusion restricted	9 (100%)	11 (69%)
Hemorrhage	6 (67%)	3 (19%)
Necrosis	4 (44%)	2 (12.5%)
Histological examination		
Yes	9 (100%)	16 (100%)
First-line treatment		
RT + N/V	8 (89%)	15 (94%)
RT + TMZ	1 (11%)	1 (6%)
TTP from end of RT		
90–180 d	2 (22%)	5 (31.5%)
180–360 d	6 (67%)	10 (62.5%)
>360 d	1 (11%)	1 (6%)
Re-irradiation at relapse		
Yes (number of re-irradiations)	7 (1)	10 (1)
Second-line treatments		
BVZ + TMZ	7 (78%)	12 (75%)
BVZ + N/V	1 (11%)	1 (6%)
Refused	1 (11%)	3 (19%)

BVZ, bevacizumab; N/V, nimotuzumab/vinorelbine; RT, radiotherapy; TMZ, temozolomide; TTP, time to progression.

observed in 19 out of 20 patients tested; p53 was overexpressed in half of the cases analyzed (10/21); ATRX proved lost in about




Figure 1. Flow chart on tumor samples analysis performed.

one-fourth of the cases tested (5/19). Ki67 expression varied from 5% to 60% (median 15%). As for the morphological features, all lesions showed an infiltrative growth pattern and the majority of tissue samples were hypercellular throughout (15/25); nuclear atypia scored as severe only in a minority of cases (3/25); mitoses were brisk in 7/20 cases. Histological and immunostaining features are detailed in Table 2.

- (b) The histone genes mutational status was investigated by Sanger sequencing or NGS in 24/25 (not performed in one case due to insufficient material). The K27M mutation was found in H3F3A for 14/24 cases (58.3%), in HIST1H3B for 9/24 patients (37.5%) and in HIST2H3C for 1/24 patients (4.2%). The only one case negative for H3K27M expression by IHC was found to be mutated by NGS. ACVR1 genes mutational status was investigated by Sanger sequencing or NGS in all but one case. ACVR1 was mutated in 8/24 cases (33.3%). NGS was performed globally in 14 cases (in 5 cases at the time of diagnosis and in 9 cases was retrospectively performed). Additional mutations found in NGS are reported in Figure 2. All detailed NGS mutation findings are listed in Supplemental material.

- (c) In the majority of the cases, the amount of tissue allowed for the evaluation of additional immunostainings, including those for therapeutic targets, that is, mTOR/p-mTOR (14/25) and BRAF-mutant (15/25). mTOR/p-mTOR pathway was overexpressed in 10/14 investigated (71%). BRAFv600E was positive in only 1/15 cases tested (7%), as confirmed by sequencing (Figure 2).

- (d) A tissue fragment was used whenever possible to set up cell cultures, allowing for the establishment of primary patient-derived cell lines in 17/25 cases (68%).

Treatment

In all, 23 patients presented to our center at the time of diagnosis and received first-line treatment with RT (59 Gy), nimotuzumab (150 mg/m²), and vinorelbine (20 mg/m²) weekly for 12 weeks, followed by nimotuzumab (150 mg/m²) and vinorelbine (25 mg/m²) every 2 weeks until progression, with concomitant valproic acid (20 mg/kg/day). Two patients who presented at the time of disease progression had been previously treated with temozolomide (75 mg/m² daily) in association to radiation (54 Gy) as first-line treatment.

Table 2. Molecular characteristics of the DIPG patients' cohort treated with or without target therapies.

	Target therapy	No target therapy
Number (%)	9 (36%)	16 (64%)
Histological and IHC findings		
Hypercellularity		
Yes, <i>n</i> (%)	5 (55.5)	10 (62.5)
No, <i>n</i> (%)	4 (44.5)	6 (37.5)
Data missing, <i>n</i> (%)	0 (0)	(0)
Mitoses		
Low, <i>n</i> (%)	4 (44.5)	9 (56)
High, <i>n</i> (%)	3 (33.5)	4 (25)
Data missing, <i>n</i> (%)	2 (22)	(19)
Atypia		
Mild, <i>n</i> (%)	4 (44.5)	8 (50)
Moderate, <i>n</i> (%)	4 (44.5)	6 (37.5)
Severe, <i>n</i> (%)	1 (11)	2 (12.5)
Data missing, <i>n</i> (%)	0 (0)	(0)
Ki67 expression		
≤5%, <i>n</i> (%)	3 (33.3)	1 (6.25)
5–15%, <i>n</i> (%)	3 (33.3)	8 (50)
>15%, <i>n</i> (%)	2 (22.3)	5 (31.25)
Data missing, <i>n</i> (%)	1 (11.1)	(12.5)
P53 expression		
>50%, <i>n</i> (%)	2 (22)	8 (50)
<50%, <i>n</i> (%)	5 (56)	5 (31.25)
Data missing, <i>n</i> (%)	2 (22)	(18.75)
ATRX		
Maintained, <i>n</i> (%)	5 (55.6)	9 (56.25)
Lost, <i>n</i> (%)	2 (22.2)	3 (18.75)
Data missing, <i>n</i> (%)	2 (22.2)	(25)
H3K27 me3		
Maintained, <i>n</i> (%)	1 (11.1)	0 (0)

(Continued)

Table 2. (Continued)

	Target therapy	No target therapy
Lost, <i>n</i> (%)	8 (88.9)	11 (68.75)
Data missing, <i>n</i> (%)	0 (0)	5 (31.25)
H3K27M IHC		
Positivity, <i>n</i> (%)	8 (89)	16 (100)
Negativity, <i>n</i> (%)	1 (11)	0 (0)
Data missing, <i>n</i> (%)	0 (0)	(0)
BRAF IHC		
Expressed, <i>n</i> (%)	1 (11)	0 (0)
Not expressed, <i>n</i> (%)	4 (44.5)	10 (62.5)
Data missing, <i>n</i> (%)	4 (44.5)	(37.5)
mTOR/pm-TOR IHC		
Expressed, <i>n</i> (%)	7 (78)	3 (19)
Not expressed, <i>n</i> (%)	0 (0)	4 (25)
Data missing, <i>n</i> (%)	2 (22)	9 (56)
Molecular findings		
Histone mutation detection	8 (88.9)	16 (100)
Type of mutation		
H3F3A, <i>n</i> (%)	3 (37.5)	11 (68.5)
HIST1H3B, <i>n</i> (%)	5 (62.5)	4 (25)
HIST2H3C, <i>n</i> (%)	0 (0)	1 (6.5)
ACVR1 detection	8 (88.9)	16 (100)
ACVR1 mutated, <i>n</i> (%)	4 (50)	4 (25)
Wild-type, <i>n</i> (%)	4 (50)	12 (75)
DIPG, diffuse intrinsic pontine glioma; IHC, immunohistochemistry.		

Re-irradiation, with a dose range of 10.8–36 Gy, was performed in patients who showed progression of disease more than 6 months after the last irradiation (17/25) and was homogeneous for both groups.

Chemotherapeutic agents used at progression were humanized anti-vascular endothelial growth factor monoclonal antibody bevacizumab (10 mg/kg



Figure 2.
IHC, immunohistochemistry.

every 2 weeks) and temozolomide (with a dosage range of 150–250 mg/m² 5 days monthly). Nimotuzumab and vinorelbine were used in association with bevacizumab in the two patients who received temozolomide as first-line treatment.

In 15/25 cases (60%) for which tumor tissue was available for IHC and DNA sequencing analysis, a number of potential targetable alterations were found. Based on these findings, 9/15 patients were treated with targeted therapy (64%). Six of 15 patients were not eligible for targeted therapy due to advanced stage of disease. Among the patients who received a targeted treatment, identified alterations included the following: mTOR/p-mTOR (5/9), *ACVR1* (2/9), mTOR/p-mTOR and *BRAFv600E* (1/9), and *PDGFRA* (1/9). Patients whose tumor tissue expressed mTOR/p-mTOR by IHC were treated with everolimus (2.5 mg/day under 30 kg of bodyweight, 5 mg/day above 30 kg). Two patients whose tumor harbored an *ACVR1* mutation received palovarotene (20 mg/day). One child was given vemurafenib (480 mg/day) in combination with everolimus due to the coexistence of *BRAFv600E* mutation and mTOR/p-mTOR expression in the tumor tissue. Pazopanib (200 mg/day) was used in a single case to target *PDGFRA*. No severe AEs were described in all the patients treated with targeted therapy; specifically, stomatitis grade II in two patients and headache grade II in one patient where discontinuation of therapy was unnecessary. Only in one patient treated with palovarotene, a cutaneous toxicity grade III, was the cause of treatment discontinuation.

Treatment groups were homogeneous as no significant differences in sex, age, molecular status, and concomitant treatments were found. Treatment details for both groups are reported in Table 3.

Radiological response to targeted treatment

Response to treatment according to the most recent RAPNO criteria²⁵ included progression disease in 3/9, stable disease in 4/9, and partial response in 2/9, documented an overall response rate in the target treatment group of 66% (6/9). Clinical timeline of four selected patients (one for each targeted treatment regimen) including MRI at indicated time points is detailed in Figure 3. Interestingly, no difference was found comparing prospective response assessment (RANO) and retrospective blinded re-evaluation using RAPNO

criteria. No correlation was found between IHC expression intensity of mTOR/p-mTOR and radiological response in patients treated with everolimus.

Survival

The 2-year OS was 19.8% for the whole study population. Specifically, the median OS time was longer in the targeted treatment group, reaching 20.26 months [interquartile range (IQR): 14.21–27.25] *versus* 14.18 months (IQR: 11.76–19.19) for the non-targeted treatment group (Figure 4), $p = 0.032$. The longest survival time (32.2 months) was observed in one patient treated with everolimus. Median SFP was 10.73 months (IQR: 6.88–14.54) in the targeted treatment cohort and 7.77 (IQR: 4.65–10.21) in the non-targeted treatment group (Figure 5), log-rank test $p = 0.23$.

The median TTP after starting targeted therapies was 5.3 months (range: 1.13–18.73).

Univariate analysis showed that the median OS in *ACVR1*-mutated cases was 19.3 months *versus* 13.9 months for wild-type (log-rank test $p = 0.14$). The K27M mutation in the H3.3 histone was associated with a significantly shorter survival compared to the H3.1 (OS 13.9 *versus* 20.3, respectively, log-rank test $p = 0.03$, Figure 6). Patients with lower p53 expression (<50% in IHC) had a better survival, with a median OS of 20.03 months *versus* 13.11 months for patients with higher expression (log-rank test $p = 0.02$, Figure 7).

Notably, the only patient refusing second-line treatment, except everolimus as a single agent, had the shortest OS (12.07 months) among the targeted therapy group (Table 3A).

Discussion

Despite the considerable progress achieved in the treatment of pediatric brain tumors, DIPG still remains a universally fatal disease with a median OS of 8–11 months.³

DIPG is standardly diagnosed using radiological imaging. Stereotactic needle biopsy is still more commonly recommended for cases with atypical radiological features or used within clinical trials which require the knowledge of the molecular alterations for patient enrollment.^{15,16}

Table 3. (A) Target therapy DIPG patients: first-line and relapse treatment details. **(B)** Control group DIPG patients: first-line and relapse treatment details.

(A)

Patients	Age at diagnosis (years)	Gender	Backbone treatment	Target treatment	Target finding	Other treatment	Sides effects	OS (months)
1	11.93	M	RTX + temozolomide	Everolimus	m/pmTOR IHC expression	bevacizumab N/V re-irradiation	Aftosis stomatitis grade II	26.57
2	5.06	F	RTX + N/V	Palovarotene	ACVR1 mutation	Bevacizumab temozolomide re-irradiation	No	14.37
3	8.77	F	RTX + N/V	Pazopanib	PDGFRA	Bevacizumab temozolomide re-irradiation	Headache grade II	18.00
4	5.04	F	RTX + N/V	Everolimus	m/pmTOR IHC expression	Bevacizumab temozolomide	No	13.97
5	5.65	F	RTX + N/V	everolimus	m/pmTOR IHC expression	No (refused)	No	12.07
6	5.98	M	RTX + N/V	everolimus	m/pmTOR IHC expression	Bevacizumab temozolomide re-irradiation	No	20.47
7	6.61	M	RTX + N/V	everolimus and vemurafenib	m/pmTOR and BRAF IHC expression	Bevacizumab temozolomide re-irradiation	Aftosis stomatitis grade II	27.50
8	7.79	F	RTX + N/V	everolimus	m/pmTOR IHC expression	Bevacizumab temozolomide re-irradiation	No	32.20
9	6.01	F	RTX + N/V	palovarotene	ACVR1 mutation	Bevacizumab temozolomide re-irradiation	Grade III skin toxicity	20.43

(B)

Patients	Age at diagnosis (years)	Gender	Backbone treatment	Other treatment	OS (months)
10	4.06	F	RTX + N/V	No (refused)	7.10
11	5.44	M	RTX + N/V	Bevacizumab temozolomide re-irradiation	14.33
12	6.10	M	RTX + N/V	Bevacizumab temozolomide	24.47
13	4.18	F	RTX + N/V	Bevacizumab temozolomide re-irradiation	21.97
14	5.56	M	RTX + N/V	Bevacizumab temozolomide re-irradiation	11.40
15	9.44	F	RTX + temozolomide	Bevacizumab N/V re-irradiation	18.53

(Continued)

Table 3. (Continued)

Patients	Age at diagnosis (years)	Gender	Backbone treatment	Other treatment	OS (months)
16	6.62	F	RTX + N/V	Bevacizumab temozolomide	13.33
17	9.31	F	RTX + N/V	Bevacizumab temozolomide re-irradiation	14.17
18	3.60	F	RTX + N/V	Bevacizumab temozolomide re-irradiation	15.03
19	6.05	M	RTX + N/V	No (refused)	7.43
20	6.66	F	RTX + N/V	Bevacizumab temozolomide re-irradiation	21.87
21	5.58	F	RTX + N/V	No (refused)	4.90
22	5.04	F	RTX + N/V	Bevacizumab temozolomide re-irradiation	17.57
23	7.73	M	RTX + N/V	Bevacizumab temozolomide re-irradiation	12.27
24	14.71	M	RTX + N/V	Bevacizumab temozolomide	7.87
25	6.35	F	RTX + N/V	Bevacizumab temozolomide re-irradiation	13.77

N, nimotuzumab; OS, overall survival; RTX, radiotherapy; V, vinorelbine.

However, autopsy and more recently biopsy have largely contributed to advance our understanding on DIPG, unveiling a biologically complex pediatric brain cancer. Beyond histology, molecular and epigenetic dysregulation outline that each tumor is slightly different from others.

This aspect potentially contributes to the substantial failure of all therapeutic approaches attempted so far.

The urgent need to improve OS rate of patients with this devastating tumor has led to reconsidering the role of biopsy, to confirm the radiological diagnosis and to collect biological samples to perform molecular investigations. Due to modern surgical techniques, the operative risk of brainstem biopsies has progressively decreased, and biopsy has been shown to be safe in experienced centers.²⁶

Since 2015, we routinely perform the stereotactic biopsy under approval of our local Ethics

Committee. The combination of robot assistance and pre-coronary approach offers an optimal diagnostic yield with a favorable risk profile, which we have already reported.²⁶ In line with our experience, other groups have shown that biopsy for DIPG patients contributes to a diagnostic detection rate ranging from 96% to 100% with a risk of mortality and morbidity lower than 5%.³⁵ As described by Puget *et al.* in a series of 130 DIPG patients,³⁶ biopsy was performed with a 100% diagnostic tissue sample obtained in all patients of our cohort at diagnosis or at disease progression. We did not record severe neurological deficits related to procedure, this finding confirming safety of the procedure. Previous recommendations limiting biopsy in DIPG patients to clinical trial settings³⁷ might not reflect the favorable safety profile that has emerged from more recent evidence.³⁸

The main aim of our study was to compare the OS and SFP in two cohorts of patients with




Figure 3. D1PG-H3K27M mutant. Radiological response to target treatment. D1PG, diffuse intrinsic pontine glioma; PD, progression disease; PR, partial response; SD, stable disease.




Figure 4. OS for DIPG patients treated by targeted agents *versus* classic treatment with number of patients at risk.
DIPG, diffuse intrinsic pontine glioma; OS, overall survival.




Figure 5. Survival after first relapse for DIPG patients treated by targeted agents *versus* classic treatment with number of patients at risk.
DIPG, diffuse intrinsic pontine glioma.

radiological and molecularly confirmed diagnosis of DIPG, treated with either our standard institutional treatment or with a targeted treatment.

Upon diagnosis at our center, 23/25 patients received first-line backbone treatment with focal irradiation associated with nimotuzumab and vinorelbine¹⁵;




Figure 6. OS for DIPG patients stratified by histone mutation type with the number of patients at risk. DIPG, diffuse intrinsic pontine glioma; OS, overall survival.

2/25 patients, prior to admission to our hospital, had received focal RT with temozolomide.

At disease progression, 23/25 patients received second-line treatment with bevacizumab and temozolomide, while second-line treatment with nimotuzumab and vinorelbine was reserved for the two patients who received temozolomide as first-line treatment. Re-irradiation was reserved, according to the literature available, to those patients in whom 6 months have relapsed since the first irradiation.³¹

Based on the molecular data and after discussion with the molecular tumor board, at the TTP, targeted therapy was given to nine patients, in association with the backbone of the second-line treatment, never during RT, neither to patients with advanced stage of disease.

We detected targetable alterations in 15/25 patients (60%), including *ACVR1*, mTOR/p-mTOR, *BRAFv600E*, and *PDGFRA*.

We detected a positivity to mTOR by IHC in 70% of our cases, a finding in line with previously reported data³⁹; our study confirms that the PI3K/AKT/mTOR signaling is the most frequently aberrant pathway in DIPG. mTOR is a serine/threonine kinase protein that has been shown to

control cell metabolism, cell survival, and cytoskeletal organization.⁴⁰ Several clinical trials have taken advantage of such target using rapamycin or an analog drug, showing antitumor activity and mild toxicity in patients⁴¹ even in the context of DIPG.^{42,43} At the time of disease progression, 5/10 patients with positive immunostaining for mTOR/p-mTOR pathway received everolimus in association to second-line therapy. Three patients, at the time of detection of the targetable lesions, had an advanced stage of disease and one was treated with palovarotene due to the *ACVR1* mutation. The only adverse event we reported in the everolimus cohort of patients was stomatitis and headache in one patient, without needing treatment discontinuation. The median OS described in the everolimus cohort was 20.47 months, including the case with the longest observed OS (32.2 months). The median SFP was 11.45 months. No correlation was found between intensity of expression of mTOR/p-mTOR, as previously described in low-grade gliomas.⁴²

BRAFv600E mutation was detected in one case which also presented mTOR/p-mTOR pathway alteration. The gene *BRAF* encodes for a serine-threonine kinase that drives cell growth. Although it represents the main oncogenic feature among low-grade gliomas, *BRAFv600E* mutations are




Figure 7. OS for DIPG patients stratified by IHC p53 expression with the number of patients at risk. DIPG, diffuse intrinsic pontine glioma; IHC, immunohistochemistry; OS, overall survival.

also found in about 6% of pediatric high-grade gliomas,²⁸ and the coexistence of H3K27M and *BRAFv600E* mutations is reported in several cases of pediatric gliomas.⁴³ Our patient received a combined treatment with vemurafenib and everolimus, achieving 27.5 months of OS and an SFP of 16.42 months. Our patient developed grade II stomatitis, which is described as potential side effect following treatment with everolimus.

Recurrent activating mutations in *ACVR1* gene have been reported in 21% of DIPG patients.¹⁸ In the *ACVR1*-mutated population, a marked female predominance and a longer OS compared to DIPG patients with wild-type *ACVR1* (median 14.9 months *versus* 10.9 months) has been reported.¹⁸ In our study cohort, *ACVR1* mutations were found in 33.3% of patients. Gain-of-function mutations in the Type I Bone Morphogenic Protein (BMP) receptor *ACVR1* have been identified in Fibrodysplasia Ossificans Progressiva (FOP) as a germline mutation. The role of somatic *ACVR1* mutation in DIPG remains under investigation.⁴⁴ Palovarotene is a retinoic receptor agonist active against BMP signaling. Previous reports in patients with FOP showed some benefit upon treatment with palovarotene.⁴⁵ Gojo *et al.*³⁴ described the first case of DIPG harboring a *ACVR1* mutation treated by palovarotene, resulting in disease stabilization

lasting 30 weeks and providing first evidence of this approach for H3K27M-*ACVR1* concurrently mutated tumors. In our targeted therapy group, palovarotene was used for two patients. The OS reported was 14.3 and 20.4 months, and SFP was 6.2 and 13.5 months, respectively. Cutaneous toxicity is the most common side effect of palovarotene,⁴⁶ and a toxicity grade III was the cause of treatment discontinuation for one of our patients.

Due to the small size of the tissue, NGS was performed globally in 14 patients, and *PDGFRA* mutation was detected in one case. *PDGFRA* can be targeted using tyrosine-kinase inhibitors (TKIs).³⁹ Specifically, pazopanib is a second-generation multi-targeted TKI against *VEGFR-1*, 2 and 3, *PDGFRA*, *PDGFR-beta*, and *c-kit*,^{47,48} which has shown activity and good tolerability in patients with advanced renal cell carcinoma and soft-tissue sarcomas.^{49,50} In our case, the patient was treated with pazopanib after first progression of the disease. The OS was 18 months and SFP 7.58 months. During treatment, grade II headache was detected.

As mentioned, 9/25 patients were treated with a targeted therapy. Comparing treatment and non-targeted treatment group, the median OS in the group treated with targeted agents was

significantly different with 20.26 months (IQR: 14.21–27.25) *versus* 14.18 months (IQR: 11.76–19.19) in the control group. The longest OS registered was 32.2 months in a patient with mTOR/p-mTOR overexpression and treated with everolimus. Moreover, the median SFP time was 10.73 months (IQR: 6.88–14.54) in the targeted treatment cohort and 7.77 (IQR: 4.65–10.21) in the control group. Only 1/9 patients in the target group treated with palovarotene experienced a grade III toxicity, which led to the suspension of treatment. No toxicity was registered in the non-targeted treatment group. No severe adverse events were reported in both groups.

In our experience, everolimus was the treatment that conferred the best OS. Notably, the only patient received everolimus as a single agent had the worst OS, suggesting the advantage of a combined therapeutic approach.

The only previous series described in literature that was treated with targeted agents, either at diagnosis or at disease progression and received backbone therapy including focal irradiation was published by Gojo *et al.*,³⁴ who reported the data of nine patients with H3K27M mutant diffuse midline glioma which included seven DIPGs. Targeted therapy included inhibition of the PI3K/AKT/mTOR pathway, MAPK signaling, immunotherapy, receptor tyrosine kinase inhibition, and retinoic receptor agonist. The overall response rate described was 78% including one complete remission, three partial responses, and three stable diseases; median TTP was 29 weeks. In our targeted therapy cohort, the response rate was 66% (four stable disease and two partial response). The different response in our study compared to Gojo *et al.* may be related to our selected population that include only DIPG and not DMG patients. Conversely, median OS described by Gojo *et al.* in target population was shorter than that of our patients (16.5 months *versus* 20.26 months).³⁴

The decision to treat patients on the basis of target detection *tout court* might be a limitation of our study. Development of an integrated data platform with bioinformatics tools has been advocated to guide precision medicine approaches and standardize treatment response assessment.⁵¹

Even though re-irradiation has been shown to improve OS, it was equally represented in our

study groups, suggesting a negligible role in determining the outcome differences we observed.

To the best of our knowledge, this is the first study reporting on a DIPG population treated by targeted therapies in comparison to the standard treatment currently utilized in our institution. Despite the limitations of the study in terms of the small sample size and the retrospective design, we find our results to be promising. These results showed an improvement in OS and SFP. A strong re-consideration of tumor biopsy as routine practice in patients with DIPG diagnosis is required. If practiced in experienced centers, biopsy would certainly allow for the detection of molecular alterations and the use of more targeted therapies. Based on our preliminary data that suggest prognostic advantage and the relatively low risk of severe side effects, we strongly advocate to reconsider performing a biopsy on all DIPG patients at diagnosis or at progression, according to the patient's clinical conditions. This allows for the detection of potential molecular driver alterations that can be targetable and subsequently adding targeted drugs to first-line treatment with the intent to improve the OS rate of this severe disease.

Declarations

Ethics approval and consent to participate

All targeted drugs were given for compassionate use and Ethics Committee approval was obtained for every case. Biological samples were collected in accordance with the Ethics Committee of the Bambino Gesù Children's Hospital (Ethics Committee Approvals N°1343/2018, N°969/2015, N°1952/2019) and with the 1964 Helsinki Declaration which includes its later amendments or comparable ethical standard; written informed consent was obtained by patient's legal guardian.

Consent for publication

Not applicable.

Author contribution(s)

Giada Del Baldo: Conceptualization; Data curation; and Writing – original draft.

Andrea Carai: Conceptualization; Methodology; and Writing – original draft.

Rachid Abbas: Data curation; Formal analysis; and Software.

Antonella Cacchione: Data curation and Visualization.

Mara Vinci: Data curation; Investigation; and Visualization.

Valentina Di Ruscio: Data curation.

Giovanna Stefania Colafati: Data curation.

Sabrina Rossi: Data curation; Investigation.

Francesca Diomedi Camassei: Investigation.

Nicola Maestro: Investigation.

Sara Temelso: Investigation.

Giulia Pericoli: Investigation.

Emmanuel De Billy: Investigation.

Isabella Giovannoni: Investigation.

Alessia Carboni: Data curation.

Martina Rinelli: Investigation.

Emanuele Agolini: Investigation.

Alan Mackay: Investigation.

Chris Jones: Investigation.

Silvia Chiesa: Data curation.

Mario Balducci: Data curation.

Franco Locatelli: Conceptualization; Supervision; and Writing – review & editing.

Angela Mastronuzzi: Conceptualization; Supervision; and Writing – review & editing.

Acknowledgements

The authors thank Megan Eckley for helping in the English final version.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by Italian Ministry of Health Ricerca Corrente, DIPG Italia and Il coraggio dei bambini Onlus. MV is a CwCUK Fellow.

Competing Interests

The authors declare that there is no conflict of interest.

Availability of data and materials

Not applicable.

Supplemental material

Supplemental material for this article is available online.

References

1. Panditharatna E, Yaeger K, Kilburn LB, *et al.* Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape. *Cancer Genet* 2015; 208: 367–373.
2. Cooney T, League-Pascual J, Lane A, *et al.* HG-109contemporary survival endpoints: an international diffuse intrinsic pontine glioma registry study. *Neuro Oncol* 2016; 18: iii73–iii74.
3. Hargrave D, Bartels U and Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. *Lancet Oncol* 2006; 7: 241–8.
4. Kebudi R, Cakir FB, Bay SB, *et al.* Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature. *Childs Nerv Syst* 2019; 35: 83–89.
5. Colafati GS, Voicu IP, Carducci C, *et al.* Direct involvement of cranial nerve V at diagnosis in patients with diffuse intrinsic pontine glioma: a potential magnetic resonance predictor of short-term survival. *Front Oncol* 2019; 9: 204.
6. Frazier JL, Lee J, Thomale UW, *et al.* Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. *J Neurosurg Pediatr* 2009; 3: 259–269.
7. Korones DN, Fisher PG, Kretschmar C, *et al.* Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. *Pediatr Blood Cancer* 2008; 50: 227–230.
8. Cohen KJ, Heideman RL, Zhou T, *et al.* Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. *Neuro Oncol* 2011; 13: 410–416.
9. Freeman CR and Farmer J-P. Pediatric brain stem gliomas: a review. *Int J Radiat Oncol Biol Phys* 1998; 40: 265–271.
10. Jansen MHA, van Vuurden DG, Vandertop WP, *et al.* Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. *Cancer Treat Rev* 2012; 38: 27–35.
11. Kebudi R and Cakir FB. Management of diffuse pontine gliomas in children: recent developments. *Pediatr Drugs* 2013; 15: 351–362.

12. Kebudi R, Cakir FB, Agaoglu FY, *et al.* Pediatric diffuse intrinsic pontine glioma patients from a single center. *Childs Nerv Syst* 2013; 29: 583–588.
13. Robison NJ and Kieran MW. Diffuse intrinsic pontine glioma: a reassessment. *J Neurooncol* 2014; 119: 7–15.
14. Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, *et al.* Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries. *J Clin Oncol* 2018; 36: 1963–1972.
15. Massimino M, Biassoni V, Miceli R, *et al.* Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. *J Neurooncol* 2014; 118: 305–312.
16. Schumacher M, Schulte-Mönting J, Stoeter P, *et al.* Magnetic resonance imaging compared with biopsy in the diagnosis of brainstem diseases of childhood: a multicenter review. *J Neurosurg* 2007; 106: 111–119.
17. Mackay A, Burford A, Molinari V, *et al.* Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY Phase II randomized trial. *Cancer Cell* 2018; 33: 829–842.e5.
18. Castel D, Philippe C, Calmon R, *et al.* Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. *Acta Neuropathol* 2015; 130: 815–827.
19. Taylor KR, Mackay A, Truffaux N, *et al.* Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. *Nat Genet* 2014; 46: 457–461.
20. Wu G, Broniscer A, McEachron TA, *et al.* Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. *Nat Genet* 2012; 44: 251–253.
21. Schwartzentruber J, Korshunov A, Liu X-Y, *et al.* Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* 2012; 482: 226–231.
22. Buczkowicz P and Hawkins C. Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma. *Front Oncol* 2015; 5: 147.
23. Mueller S, Jain P, Liang WS, *et al.* A pilot precision medicine trial for children with diffuse intrinsic pontine glioma—PNOC003: a report from the Pacific Pediatric Neuro-Oncology Consortium. *Int J Cancer* 2019; 145: 1889–1901.
24. Chukwueke UN and Wen PY. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. *CNS Oncol* 2019; 8: CNS28.
25. Cooney TM, Cohen KJ, Guimaraes CV, *et al.* Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. *Lancet Oncol* 2020; 21: e330–e336.
26. Carai A, Mastronuzzi A, De Benedictis A, *et al.* Robot-assisted stereotactic biopsy of diffuse intrinsic pontine glioma: a single-center experience. *World Neurosurg* 2017; 101: 584–588.
27. Pericoli G, Petrini S, Giorda E, *et al.* Integration of multiple platforms for the analysis of multicolor fluorescent marking technology applied to pediatric GBM and DIPG. *Int J Mol Sci* 2020; 21: 6763.
28. Izquierdo E, Yuan L, George S, *et al.* Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. *Oncotarget* 2017; 8: 112036–112050.
29. Mackay A, Burford A, Carvalho D, *et al.* Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. *Cancer Cell* 2017; 32: 520–537.e5.
30. Vinci M, Burford A, Molinari V, *et al.* Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. *Nat Med* 2018; 24: 1204–1215.
31. Janssens GO, Gandola L, Bolle S, *et al.* Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. *Eur J Cancer* 2017; 73: 38–47.
32. Fouladi M, Laningham F, Wu J, *et al.* Phase I study of everolimus in pediatric patients with refractory solid tumors. *J Clin Oncol* 2007; 25: 4806–4812.
33. Del Bufalo F, Ceglie G, Cacchione A, *et al.* BRAF V600E inhibitor (Vemurafenib) for BRAF V600E mutated low grade gliomas. *Front Oncol* 2018; 8: 526.
34. Gojo J, Pavelka Z, Zapletalova D, *et al.* Personalized treatment of H3K27M-mutant pediatric diffuse gliomas provides improved therapeutic opportunities. *Front Oncol* 2020; 9: 1436.

35. Puget S, Blauwblomme T and Grill J. Is biopsy safe in children with newly diagnosed diffuse intrinsic pontine glioma? *Am Soc Clin Oncol Educ Book* 2012; 32: 629–633.
36. Puget S, Beccaria K, Blauwblomme T, *et al.* Biopsy in a series of 130 pediatric diffuse intrinsic pontine gliomas. *Childs Nerv Syst* 2015; 31: 1773–1780.
37. Walker DA, Liu JF, Kieran M, *et al.* A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. *Neuro Oncol* 2013; 15: 462–468.
38. Pfaff E, El Damaty A, Balasubramanian GP, *et al.* Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. *Eur J Cancer* 2019; 114: 27–35.
39. Rashed WM, Maher E, Adel M, *et al.* Pediatric diffuse intrinsic pontine glioma: where do we stand? *Cancer Metastasis Rev* 2019; 38: 759–770.
40. Wu G, Diaz AK, Paugh BS, *et al.* The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. *Nat Genet* 2014; 46: 444–450.
41. Shimobayashi M and Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. *Nat Rev Mol Cell Biol* 2014; 15: 155–162.
42. Cacchione A, Lodi M, Carai A, *et al.* Upfront treatment with mTOR inhibitor everolimus in pediatric low-grade gliomas: a single-center experience. *Int J Cancer* 2021; 148: 2522–2534.
43. Bautista F, Paci A, Minard-Colin V, *et al.* Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas: vemurafenib in pediatric high-grade gliomas. *Pediatr Blood Cancer* 2014; 61: 1101–1103.
44. Han HJ, Jain P and Resnick AC. Shared ACVR1 mutations in FOP and DIPG: opportunities and challenges in extending biological and clinical implications across rare diseases. *Bone* 2018; 109: 91–100.
45. Chakkalakal SA, Uchibe K, Convente MR, *et al.* Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human *ACVR1*^{R206H} Fibrodysplasia Ossificans Progressiva (FOP) mutation. *J Bone Miner Res* 2016; 31: 1666–1675.
46. Wentworth KL, Masharani U and Hsiao EC. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. *Br J Clin Pharmacol* 2019; 85: 1180–1187.
47. Sonpavde G, Hutson TE and Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. *Expert Opin Investig Drugs* 2008; 17: 253–261.
48. Iwamoto FM, Lamborn KR, Robins HI, *et al.* Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). *Neuro Oncol* 2010; 12: 855–861.
49. Masini C, Vitale MG, Maruzzo M, *et al.* Safety and efficacy of pazopanib in first-line metastatic renal-cell carcinoma with or without renal failure: CORE-URO-01 study. *Clin Genitourin Cancer* 2019; 17: e150–e155.
50. Cesne AL, Bauer S, Demetri GD, *et al.* Safety and efficacy of pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. *BMC Cancer* 2019; 19: 794.
51. Kwang Chae Y, Pan PA, Davis AA, *et al.* Path toward precision oncology: review of targeted therapy studies and tools to aid in defining “actionability” of a molecular lesion and patient management support. *Mol Cancer Ther* 2017; 16: 2645–2655.

Visit SAGE journals online
journals.sagepub.com/
home/tam

 SAGE journals